Phase 4 Depression and Anxiety Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a depression severity score above 20 on a standard rating scale called the MADRS, and who are already planned to receive electroconvulsive therapy (ECT)
- People whose depression meets the definition of treatment-resistant depression (TRD), meaning at least two standard antidepressant medications have been tried for an adequate length of time without sufficient improvement
Who may not be able to join:
- People who are unable to give informed consent to participate in the trial
- People whose overall physical health is rated at a high-risk level (a score of 4 or above on a scale used by anaesthesiologists to assess surgical risk)
- People who have an implanted electronic medical device, such as a pacemaker, defibrillator, spinal cord stimulator, deep brain stimulator, or implanted drug pump
- People who have a diagnosis of schizoaffective disorder
- Women who could potentially become pregnant and either decline a urine pregnancy test or receive a positive result on that test
- People who have a known allergy to any of the study medications or their ingredients
- People with a serious physical health condition that the treating psychiatrist or anaesthesiologist considers to be a reason to avoid ECT — this includes certain heart conditions (such as uncontrolled high blood pressure), breathing problems, brain or blood vessel conditions, raised pressure inside the skull (including glaucoma), or a history of seizures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jonathan Gamble, MD, University of Saskatchewan
Phone: 3066551183
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of treatments required to reach disease remission
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.